Axsome Therapeutics (AXSM) AI Stock Analysis

• Market Cap: $7.62B
• Dividend Yield: N/A
• Average Volume (3M): 559.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: 65.83%
• EPS Growth: 28.50%
• Country: US
• Employees: 712
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.94
• Shares Outstanding: 50,412,640
• 10 Day Avg. Volume: 620,216
• 30 Day Avg. Volume: 559,685
• PEG Ratio: -1.03
• Price to Book (P/B): 71.10
• Price to Sales (P/S): 10.51
• P/FCF Ratio: -31.50
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 10.63
• Enterprise Value/Gross Profit: 11.58
• Enterprise Value/Ebitda: -28.11
• 1Y Price Target: $175.25
• Price Target Upside: 15.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -3.8
• Revenue Forecast (FY): $628.71M

• Rating: 55 Neutral
• Price Target: $153.00 ▲(1.19% Upside)

Axsome Therapeutics' stock score is driven by strong technical indicators and revenue growth, but is tempered by significant financial challenges and valuation concerns. The company's high leverage and ongoing net losses present risks, while the positive momentum in stock price and strategic product performance offer potential upside.

Positive Factors

Revenue Growth

Strong revenue growth indicates effective commercialization and market acceptance of products, supporting long-term financial health.

R&D Pipeline Advancements

Advancements in the R&D pipeline suggest potential for future product launches, enhancing long-term growth prospects.

Commercial Strategy Success

Successful commercial strategy and increased coverage expand market reach, supporting sustained revenue growth.

Negative Factors

High Debt Levels

High leverage increases financial risk and can limit operational flexibility, impacting long-term financial stability.

Profitability Challenges

Ongoing profitability issues may hinder reinvestment and growth, affecting the company's ability to sustain operations long-term.

Negative Operating Cash Flow

Negative operating cash flow can strain resources and limit the company's ability to finance growth and innovation.

Axsome Therapeutics Business Overview & Revenue Model

Company Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

How the Company Makes Money

Axsome Therapeutics generates revenue primarily through the commercialization of its pharmaceutical products. The company has received regulatory approvals for its lead product, AXS-05, which contributes to its revenue through sales in the market. Additionally, Axsome may engage in strategic partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on sales of partnered products. Research grants and government funding for clinical trials may also serve as supplementary revenue sources. As the company advances its pipeline and achieves regulatory milestones, it aims to enhance its revenue streams through the introduction of additional products to the market.

Axsome Therapeutics Financial Statement Overview

Summary

Axsome Therapeutics demonstrates strong revenue growth and gross profit margins, but faces significant profitability and cash flow challenges. High leverage and negative returns on equity highlight financial risks. The company needs to address operational inefficiencies and improve cash flow management to enhance financial stability.

Income Statement

Axsome Therapeutics shows strong gross profit margins consistently above 90%, indicating efficient cost management relative to revenue. However, the company is experiencing significant net losses, with a negative net profit margin of -40.89% in the TTM period. Revenue growth is positive, with a notable 13.38% increase in the TTM, but the persistent negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 2.93 in the TTM, suggesting significant leverage and potential financial risk. Return on equity is negative, reflecting the company's ongoing losses. The equity ratio is not directly provided, but the high leverage and negative ROE indicate financial instability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a declining free cash flow growth rate of -16.50% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash flow is closely aligned with reported net income, albeit negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	561.26M	385.69M	270.60M	50.04M	0.00	0.00
Gross Profit	515.60M	352.39M	244.53M	44.84M	0.00	0.00
EBITDA	-212.34M	-272.60M	-224.99M	-175.40M	-124.63M	-100.31M
Net Income	-229.53M	-287.22M	-239.24M	-187.13M	-130.40M	-102.90M
Balance Sheet
Total Assets	669.25M	568.50M	588.24M	331.48M	87.79M	186.13M
Cash, Cash Equivalents and Short-Term Investments	325.27M	315.35M	386.19M	200.84M	86.47M	183.88M
Total Debt	218.60M	192.96M	186.37M	94.68M	49.71M	50.12M
Total Liabilities	595.52M	511.48M	397.26M	221.92M	72.15M	72.34M
Stockholders Equity	73.73M	57.02M	190.98M	109.56M	15.63M	113.79M
Cash Flow
Free Cash Flow	-101.04M	-128.68M	-145.66M	-117.21M	-108.53M	-78.50M
Operating Cash Flow	-100.95M	-128.41M	-145.08M	-116.51M	-108.23M	-78.46M
Investing Cash Flow	-439.00K	-270.00K	-582.00K	-53.70M	-308.00K	-45.89K
Financing Cash Flow	99.32M	57.84M	331.01M	284.58M	11.13M	42.41M

Axsome Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 151.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXSM, the sentiment is Positive. The current price of 151.2 is above the 20-day moving average (MA) of 139.90, above the 50-day MA of 129.22, and above the 200-day MA of 116.70, indicating a bullish trend. The MACD of 5.44 indicates Negative momentum. The RSI at 71.23 is Negative, neither overbought nor oversold. The STOCH value of 83.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AXSM.

Axsome Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYTK	58 Neutral	$8.22B	―	―	―	2609.26%	-17.08%
RNA	56 Neutral	$10.73B	―	-32.44%	―	106.27%	-43.90%
AXSM	55 Neutral	$7.62B	―	-275.50%	―	65.83%	28.50%
RYTM	52 Neutral	$7.11B	―	-240.36%	―	54.92%	28.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	47 Neutral	$5.01B	―	-22.60%	―	74.91%	31.54%
NUVL	43 Neutral	$7.96B	―	-38.79%	―	―	-52.84%

Axsome Therapeutics Corporate Events

Axsome Therapeutics Reports Strong Q3 2025 Growth

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for central nervous system disorders, offering a range of FDA-approved and investigational products targeting serious psychiatric and neurological conditions.

Axsome Therapeutics Reports 63% Revenue Growth in Q3 2025

On November 3, 2025, Axsome Therapeutics reported a significant 63% year-over-year growth in net product revenue for the third quarter of 2025, totaling $171 million. The company also submitted a supplemental NDA for AXS-05 for Alzheimer’s disease agitation, highlighting its strong commercial performance and pipeline progress. The financial results reflect robust sales of AUVELITY, SUNOSI, and the newly launched SYMBRAVO, positioning Axsome for continued growth and innovation in the CNS disorder treatment market.

The most recent analyst rating on (AXSM) stock is a Hold with a $136.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Axsome Therapeutics Advances Study on Solriamfetol for Binge Eating Disorder

Axsome Therapeutics Inc. is conducting an open-label Phase 3 study titled ‘An Open-Label Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults with Binge Eating Disorder’. The study aims to evaluate the safety and efficacy of solriamfetol for treating binge eating disorder (BED) in adults, highlighting its potential significance in addressing this condition.

Axsome Therapeutics’ Promising Phase 3 Trial for Shift Work Disorder

Study Overview: Axsome Therapeutics Inc. is conducting a Phase 3 trial titled ‘A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder.’ The study, known as SUSTAIN, aims to evaluate the effectiveness and safety of solriamfetol in treating adults suffering from excessive sleepiness due to shift work disorder, a condition affecting many in the workforce.

Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention

Study Overview: Axsome Therapeutics Inc. is conducting a study titled A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms. The study aims to evaluate the efficacy of AXS-05 compared to bupropion in preventing the relapse of depressive symptoms in individuals with major depressive disorder (MDD) who have responded to AXS-05 treatment. This research is significant as it explores potential advancements in maintaining mental health stability for MDD patients.

Axsome Therapeutics Advances Phase 3 Trial for Binge Eating Disorder Treatment

Study Overview: Axsome Therapeutics Inc. is conducting a Phase 3 clinical trial titled ‘A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)’. The study aims to evaluate the efficacy and safety of solriamfetol in treating adults with binge eating disorder, a condition characterized by recurrent episodes of eating large quantities of food.

Axsome Therapeutics Receives Paragraph IV Certification Notice

On August 19, 2025, Axsome Therapeutics received a Paragraph IV Certification Notice from Apotex, indicating that Apotex has filed an ANDA with the FDA to produce a generic version of Axsome’s Symbravo®. Axsome plans to respond to this notice, which could impact its market position and stakeholder interests.

The most recent analyst rating on (AXSM) stock is a Buy with a $189.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.

Axsome Therapeutics’ Earnings Call Highlights Robust Growth

Axsome Therapeutics Inc. Reports Strong Revenue Growth and Promising Pipeline Developments

Axsome Therapeutics Reports Strong Q2 2025 Growth

Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders, with a portfolio that includes FDA-approved medications for depression, sleep disorders, and migraine, as well as a robust pipeline of late-stage development programs.

Axsome Therapeutics Reports Strong Q2 2025 Performance

On August 4, 2025, Axsome Therapeutics reported a significant financial performance for the second quarter of 2025, with a 72% year-over-year increase in net product revenue, reaching $150 million. The company highlighted the successful launch of SYMBRAVO for migraines and the strong sales growth of AUVELITY and SUNOSI. Axsome is progressing with regulatory submissions for AXS-05 and AXS-12, aiming to expand its product pipeline addressing serious psychiatric and neurological conditions. The company also reported a reduced net loss compared to the previous year, indicating improved financial health.

The most recent analyst rating on (AXSM) stock is a Buy with a $190.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.